Amgen earnings beat by $0.51, revenue topped estimates

Investing.com – Amgen (NASDAQ: ) reported second quarter EPS of $5.00, $0.51 better than the analyst estimate of $4.49. Revenue for the quarter came in at $7B versus the consensus estimate of $6.67B.

Guidance

Amgen sees FY 2023 EPS of $17.80-$18.80 versus the analyst consensus of $17.75.

Amgen sees FY 2023 revenue of $26.60B-$27.40B versus the analyst consensus of $26.56B.

Amgen’s stock price closed at $230.70. It is down -2.46% in the last 3 months and down -6.59% in the last 12 months.

Amgen saw 7 positive EPS revisions and 12 negative EPS revisions in the last 90 days. See Amgen’s stock price’s past reactions to earnings here.

According to InvestingPro, Amgen’s Financial Health score is “great performance”.

Check out Amgen’s , and Amgen’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar